Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2011 Sep 22;6(9):e24901. doi: 10.1371/journal.pone.0024901

Profiling of the Tetraspanin CD151 Web and Conspiracy of CD151/Integrin β1 Complex in the Progression of Hepatocellular Carcinoma

Ranjan Prasad Devbhandari 1,#, Guo-Ming Shi 1,#, Ai-Wu Ke 2,#, Fei-Zhen Wu 3,#, Xiao-Yong Huang 1, Xiao-Ying Wang 1, Ying-Hong Shi 1, Zhen-Bin Ding 1, Yang Xu 1, Zhi Dai 1, Jia Fan 4,*, Jian Zhou 1,*
Editor: John Luk5
PMCID: PMC3178554  PMID: 21961047

Abstract

Tetraspanin CD151 has been implicated in metastasis through forming complexes with different molecular partners. In this study, we mapped tetraspanin web proteins centered on CD151, in order to explore the role of CD151 complexes in the progression of hepatocellular carcinoma (HCC). Immunoprecipitation was used to isolate tetraspanin complexes from HCCLM3 cells using a CD151 antibody, and associated proteins were identified by mass spectrometry. The interaction of CD151 and its molecular partners, and their roles in invasiveness and metastasis of HCC cells were assayed through disruption of the CD151 network. Finally, the clinical implication of CD151 complexes in HCC patients was also examined. In this study, we identified 58 proteins, characterized the tetraspanin CD151 web, and chose integrin β1 as a main partner to further investigate. When the CD151/integrin β1 complex in HCC cells was disrupted, migration, invasiveness, secretion of matrix metalloproteinase 9, and metastasis were markedly influenced. However, both CD151 and integrin β1 expression were untouched. HCC patients with high expression of CD151/integrin β1 complex had the poorest prognosis of the whole cohort of patients. Together, our data show that CD151 acts as an important player in the progression of HCC in an integrin β1-dependent manner.

Introduction

The dismal prognosis of hepatocellular carcinoma (HCC) is mostly attributed to high metastasis. This disease has attracted the considerable attention of investigators from the bench to the clinic [1], [2]. Metastasis is a multi-step cascade involving migration of tumor cells from the original site, evasion of host defense systems, subsequent location to distant organs, and growth of secondary tumors [3], [4]. Throughout the cascade, from its original location to distant sites, there is constant interplay between metastasizing tumor cells and the changing microenvironment, leading to the breakdown of normal cell adhesion which facilitates cell migration [5].

Integrins, which are composed of a non-covalent heterodimer of α- and β-subunits, mediate signals from the extracellular matrix (ECM) that help to regulate cell migration, differentiation, cell cycle progression, apoptosis, phagocytosis, ECM assembly, and metalloproteinase activity [5]. Within the integrin family, integrin β1 has been widely studied in the biology of solid tumors, as its expression positively correlates with poor prognosis in a several malignancies, including breast cancer [6] and HCC [7]. These effects are mostly attributed to the binding of integrin β1 to ligands, fibronectin, and laminin, as well as the modulation of cytoskeleton-signaling associated with cell migration, ECM assembly, and metalloproteinase activity [5]. However, our previous study showed that high levels of integrin β1 expression in HepG2 cells with low metastatic potential and a high percentage of integrin β1- positive cells in most HCC samples [8]. These results indicate that the metastatic potential of HCC cells is not completely dependent on integrin β1 expression.

Tetraspanins (TM4SF) possess four transmembrane domains: a small intracellular loop, intracellular N- and C-termini with short cytoplasmic tails, and two extracellular loops, the larger of which contains a distinctive pattern of cysteine residues that helps to define the family [9]. The most striking feature of tetraspanin molecules is that they can assemble multimolecular signaling complexes at the cell surface such as integrins, membrane receptors, intracellular signaling molecules, other tetraspanins, and immunoglobulin superfamily proteins at tetraspanin-enriched microdomains (TEMs) to form “a tetraspanin web” [10], [11]. This “tetraspanin web” can thus serve as molecular facilitators or organizers of multimolecular complexes on the cell surface [9], [12], [13]. Recent studies have demonstrated that the great heterogeneity in the composition of the “tetraspanin web”, and the dynamics of tetraspanin complexes, confer great flexibility to tetraspanins that allow for specificity and functional differences [14]. For example, CD82 can form complexes with the GM2/GM3 heterodimer and inhibit cell motility through the CD82-c-Met or integrin-c-Met pathway [15]. CD82 attenuates α6 integrin-mediated cellular morphogenesis through modulation of integrin α6 signaling and internalization of integrin α6 [16]. Hence, to uncover the functions of tetraspanin proteins, it is critical to identify laterally interacting partner proteins [12], [13].

Tetraspanin CD151 (also named as SFA-1 and PETA-3), is an important member of the tetraspanin family, and has been widely studied in several malignant tumors [13], [17], [18], [19]. Evidence has demonstrated that CD151 forms complexes with integrins, c-Met, other tetraspanins, and itself, and is implicated in pathological processes associated with cancer progression [12], [20], [21]. For example, modified HeLa cells overexpressing CD151 have more migratory abilities than control cells expressing little CD151 [22]. Other reports have shown that antibodies against CD151 can inhibit cell migration [23]. Previously, we determined that CD151 was a crucial molecule involved in tumor cell invasion [18], tumor neo-angiogenesis [19], and epithelial-mesenchymal transition (EMT) [8]. We also showed that it was associated with the progression and metastasis of HCC by forming complexes with c-Met or integrin α6. This suggests that CD151 is likely to participate in metastasis through forming complexes with different molecular partners, which contributes to heterogeneous characteristics in terms of the aggressive potential and prognosis of HCC [24]. However, the role of CD151 in malignant tumors is not simple. Overexpression of CD151 significantly increases intercellular adhesiveness and delays wound closure in a scratch assays [25], [26]. Conversely, downregulation of CD151 expression promotes invasiveness of breast cancer cells [27]. Thus, CD151 is likely to possess diverse and unpredictable functions in different cellular environments. Thus, the “tetraspanin web” centered on CD151, and its interaction in HCC remains to be investigated.

A more thorough description of the composition and organization of the tetraspanin web, and deeper exploration into the interaction of tetraspanin complexes, are of importance in understanding the function of these molecules. In the present study, we performed proteomic analysis of CD151-containing complexes by mass spectrometry (MS), and then evaluated the interaction of CD151 and integrin β1 in vivo and in vitro. Finally, we assayed the roles of CD151/β1-integrin complexes in the prognosis of HCC patients.

Results

Characterization of the tetraspanin CD151 network in HCC cells

With the knowledge of the structure and functional patterns of tetraspanins, we mapped tetraspanin complexes centered on CD151, to address the interaction of CD151 with its molecular partner in HCC cells in the context of other regulatory mechanisms. In present study, we chose HCCLM3 cells to do the immuoprecipitation because HCCLM3 cells have the highest expression of CD151 protein based on our previous study [18] . After isolation of CD151-containing complexes by immunoprecipitation, proteins were eluted using the stringent detergent, Triton X-100, which dissociates tetraspanin-tetraspanin associations [28]. Proteins were then resolved by SDS-PAGE (Fig. 1A), and CD151-containing complexes were identified by mass spectrometry. A common set of 58 proteins was obtained when the significance threshold was set at p<0.05 (Table 1); identification of CD151 and integrin β1 are shown in Fig. 1B and 1C. Bioinformatic analysis of the enriched partners in various categories displayed an integrated tetraspanin network centered on CD151 in HCC cells. We found that 10 of the 57 CD151-associated partner proteins identified, were previously reported to directly or indirectly associate with CD151. Based on the type of interaction, we classified three levels of interactions in the tetraspanin network (Fig. 1D). As shown in Fig. 1D, CD151 formed the first level of complexes with tetraspanin partners integrin α3, α6, and β1 all of which were dependent on direct interactions. We also observed seven functional complexes at the second level, which indirectly interacted with CD151 (Fig. 1D). Interestingly, 47 novel molecules were identified, which unknown interacted with CD151 (Fig. 1D).

Figure 1. Identification of tetraspanin CD151 network and functional analysis.

Figure 1

Open in a new tab

CD151-containing complexes were solubilized using the mild detergent, Brij97, and were isolated by immunoprecipitation using specific CD151 mAbs. Associated proteins were eluted using Triton X-100 and separated by SDS-PAGE (A). After in-gel trypsin digestion of proteins, the resulting peptides were analyzed using LC-MS/MS (B and C). The peptides were separated by nano-HPLC. Total ion count was measured and visualized on a chromatogram (upper panel). At a precise time (e.g. 55.33 min for CD151 and 67.18 min for integrin β1, dotted straight line), the mass spectrum obtained is shown (middle panel) in which a parent ion can be selected (e.g. m/z = 643.3489 for CD151 and 1010.0838 for integrin β1, black arrow). Fragmentation of that parent ion led to MS/MS spectrum generation containing b and y ions, and thus sequence information of the parent ion (lower panel). The amino acid sequence can be deduced after searches in the NCBI database using the program SEQUEST. The putative sequence of the peptide is shown with associated Xcorr and ΔCn. This peptide sequence led to the identification of CD151 and integrin β1. These peptides were converted into a gene symbol and rearranged according to GO functional enrichment provided by DAVID website. Then, the “tetraspanin CD151 web” was organized by the cytoscape (Ver: 2.6.2, http://www.cytoscape.org/), searching target genes that interacted with CD151, and removing genes that were not contained in our target genes using a data source (NCBI Entrez EUtilities Web Service Client) (D). Gene ontology analysis of the 57 molecular partners was performed. They were classified as 13 categories of biological processes including protein folding and cell migration (MOES, TSP1, c-MET, NRP1, ITA6, ITB1 and GIPC1) according to categories of the “GO Biological Process” (E). Western blotting identified CD151 formed complexes with integrin α6 and β1 in HCCLM3 cells as well as HepG2 cells, but not in normal hepatocytes L-02 (F).

Table 1. List of identified 58 proteins.

Protein name Score Protein uniprot accession no. Theoretical molecular mass(Da) No. of peptides
Integrin β1 1037 P05556 88407 12
GRP-75 886 P38646 73635 16
Heat shock 70 kDa protein 8 560 P11142 70854 14
Integrin α3 542 P26006 118622 9
Cell proliferation-inducing gene 32 protein 497 P07814 170540 12
GRP-78 409 P11021 72288 9
p195 168 P46940 189134 4
HSP70-1/HSP70-2 168 P08107 70009 4
TP-alpha 156 P40939 82947 4
NAmPRTase 149 P43490 55487 4
CD151 128 P48509 28295 2
LDL receptor 114 P01130 95314 1
EF-1-alpha-1 109 P68104 50109 1
RuvB-like 2 106 Q9Y230 51125 3
Moesin 103 P26038 67778 2
UDPGDH 101 O60701 54989 2
PABP-1 100 P11940 70626 5
SEC16 homolog A 99 O15027 233373 2
RuvB-like 1 97 Q9Y265 50196 2
Neuropilin-1 90 O14786 103055 1
Integrin α6 88 P23229 126539 2
hnRNP Q 88 O60506 69560 2
Granulins 87 P28799 63500 1
Alpha-coat protein 87 P53621 138244 2
TIP-2 86 O14908 36027 1
CAD protein 86 P27708 242829 1
Restin 83 P30622 160891 1
PACSIN2 81 Q9UNF0 55704 4
LRP 130 81 P42704 157805 2
TCP-1-beta 77 P78371 57452 1
RP-A p70 70 P27694 68095 2
Nucleolin 66 P19338 76568 1
Cytochrome P450 27 63 Q02318 60196 1
Thrombospondin-1 61 P07996 129300 2
TCP-1-gamma 53 P49368 60495 1
HGF receptor 52 P08581 155427 2
HspB1 51 P04792 22768 1
Protein HS1 50 P27348 27764 3
TNFαR1 48 P50555 50696 2
Protein TFG 46 Q92734 43407 1
hnRNP K 45 P61978 50944 1
PAST homolog 4 44 Q9H223 61137 1
Importin-7 43 O95373 119440 2
LACS 3 43 O95573 80368 1
IMP-1 40 Q9NZI8 63417 1
Programmed cell death protein 8 40 O95831 66859 1
hnRNP M 38 P52272 77464 1
ELP1 37 O95163 150096 1
SRP54 36 P61011 55668 1
Importin subunit alpha-2 34 P52292 57826 1
hnRNP H 33 P31943 49198 1
Extended-synaptotagmin-1 32 Q9BSJ8 122780 1
Hornerin 32 Q86YZ3 282228 1
SAPS domain family member 3 31 Q5H9R7 97608 1
Clathrin heavy chain 1 31 Q00610 191493 1
Nucleoporin Nup133 31 Q8WUM0 128898 1
p59 30 Q02790 51772 1
HsGCN1 30 Q92616 292558 1
Open in a new tab

To analyze the role of molecular partners in the tetraspanin network centered on CD151 in HCC cells, we performed gene ontology (GO) analysis of the 57 molecular partner candidates. They were classified according to categories of the “GO Biological Process” as shown in Fig. 1E. Results revealed that molecular partners included proteins involved in protein folding (HSP7C, TCPB, RUVB2, COPA, TCPG, FKBP4 and GRP75), cell migration (MOES, TSP1, c-MET, NRP1, ITA6, ITB1 and GIPC1), cellular protein localization (IMA2, 1433B, SRP54, COPA, IPO7, GRP75, CLH1 and GIPC1), protein transport (IMA2, NU133, 1433B, SRP54, SC16A, COPA, IPO7, GRP75, CLH1 and GIPC1), membrane organization (EHD4, HSP7C, TSP1, LDLR, PACN2, COPA, CLH1), vesicle-mediated transport (EHD4, HSP7C, TSP1, LDLR, PACN2, SC16A, COPA and CLH1), regulation of apoptosis (TSP1, 1433B, AIFM1, HSP71, GRP78, TRAF1, GRP75 and HSPB1), protein complex assembly (SYEP, 1433B, SRP54, TRAF1, IPO7, FKBP4 and ELP1), nucleus organization (NU133 and AIFM1), nucleocytoplasmic transport (IMA2, NU133, IPO7 and GRP75), macromolecular complex subunit organization (SYEP, NU133, 1433B, SRP54, TRAF1, IPO7, FKBP4 and ELP1), integrin-mediated signaling pathway (ITA3, ITA6 and ITB1) and regulation of cellular protein metabolic processes (TSP1, GCN1L, IF2B1, 1433B, HSPB1 and GIPC1). Among them, proteins related to protein folding and cell migration represented the most abundant groups of proteins (Fig. 1E), demonstrating that CD151 forms functional complexes with these molecular partners to participate in biological processes of HCC, including metastasis.

Consistent with previous results [8], we identified integrin α6 and β1 as molecular partners for CD151 in HCCLM3 cells and HepG2 cells as well, but not in normal hepatocytes L-02 expressing little CD151 (Fig. 1F). To further explore the function and interaction between CD151 and its partners in HCC cells, we chose integrin β1 as a core partner for the follow reasons: (i) among 57 tetraspanin partners, integrin β1 had the highest Mascot score (Table 1), (ii) analysis of the “GO Biological Process” for mapping of the tetraspanin network, showed that proteins associated with cell migration were the second most abundant category of tetraspanin partners, of which integrin β1 played a crucial role in cell migration, (iii) it is well documented that integrin β1 is tightly associated with the progression of malignant tumors, (iv) among 5 integrin subunits, integrin β1 expressed at high level in HCCLM3 cells (Fig. S1). However, metastasis of HCC is not completely dependent on integrin β1 expression, as discussed in the ‘Introduction’. Therefore, we investigated the interaction of the CD151/integrin β1 complex, and its role in invasion and metastasis.

Location and expression of CD151/integrin β1 complexes in HCC cells

An immunofluorescence assay showed that CD151 and integrin β1 were co-localized on the plasma membrane in HCCLM3 cells (Fig. 2A). In line with our previous reports [8], the protein expression of CD151 in HCC cells positively correlated to its metastatic potential (Fig. 2B). Interestingly, all HCC cells used in this study had high protein expression of integrin β1 (Fig. 2B). Flow cytometry showed a high proportion of integrin β1-positive cells in HCCLM3 cells, MHCC97H, MHCC97L, PLC/PRF/5, Hep3B and HepG2 cells (Fig. 2C), indicating that the metastatic potential of HCC cells is not associated with the percentage of integrin β1-positive cells. The expression of CD151 or integrin β1 in HCCLM3-shRNA was downregulated at both the protein and mRNA levels compared to parental cell lines (Fig. 2D and E). As expected, the level of integrin β1 expression remained unchanged in shRNA-CD151-HCCLM3 cells, and vice versa (Fig. 2D and E), suggesting that the expression of integrin β1 is independent of that of CD151.

Figure 2. Location and expression of CD151/integrin β1 complex in HCC cells.

Figure 2

Open in a new tab

An immunofluorescence assay was performed. CD151 was stained with red and integrin β1 was stain with green. CD151 and integrin β1 co-localized on the plasma membrane in HCCLM3 cells (A). Western blotting revealed that the expression of CD151 in high metastatic HCCLM3 cells was highest and non-metastatic HepG2 cells presented the lowest levels of CD151 among six HCC cells. The results also demonstrated high expression of integrin β1 in six HCC cells lines (B). Flow cytometry analysis showed that the high proportion of integrin β1-positive cells were in six HCC cells (C). After transfection, HCCLM3-shRNA 2# was most efficient in downregulating the expression of integrin β1 at both the protein and mRNA levels (D). The level of integrin β1 expression remained unchanged in HCC interfered with CD151 shRNA, and vice versa (E).

CD151 increases invasion and mobility of HCC cells in an integrin β1-dependent manner

Invasion assays were used to investigate the interaction of the CD151/integrin β1 complex and its role in the invasiveness of HCC cells. Results showed that the number of invaded HCCLM3-mock cells were 40±10, significantly higher than those of shRNA-CD151-HCCLM3 (22±8) and shRNA-integrin β1-HCCLM3 (20±9) cells (Fig. 3A and B). After transfection of CD151 cDNA into HepG2 cells, the number of invaded HepG2-CD151 cells was higher than that of HepG2-mock cells (32±8 verse 16±5). Of note, when CD151/integrin β1 expression in HepG2-CD151 cells was silenced, the number of invaded cells markedly decreased (17±5 and 15±6, Fig. 3A and B), indicating that CD151 and integrin β1 have synergistic roles in the invasiveness of HCC cells.

Figure 3. CD151 increased invasion, mobility and metastasis of HCC cells in an integrin β1-dependent manner.

Figure 3

Open in a new tab

Transwell assays showed that the number of invasive HCCLM3-mock and HepG2-CD151 cells were significantly higher than those of shRNA-CD151-HCCLM3, shRNA-integrin β1-HCCLM3 cells and HepG2-CD151-shRNA-CD151, HepG2-CD151-shRNA-integrin β1, respectively (A and B). Wound healing assays revealed an apparent decrease in the mobility of HCCLM3 cells transfected with shRNA-CD151 or shRNA-integrin β1. Similarly, disruption of CD151 or integrin β1 in HepG2-CD151 cells, HepG2-CD151-shRNA-CD151 or shRNA-integrin β1 showed the impaired mobility (C). ELISA showed that the concentration of MMP9 in the supernatant from HCCLM3-mock and HepG2-CD151 cells was significantly higher than that of shRNA-CD151-HCCLM3 cells, shRNA-integrin β1-HCCLM3 cells and HepG2-CD151-shRNA-CD151 or shRNA-integrin β1, respectively (D). However, no significant changes of MMP2 were observed in HCC cells after interference with CD151 or integrin β1 (D). After construction of metastasis model in situ, tumor volumes of HCCLM3-mock-derived xenografts were significantly larger than those of HCCLM3-shRNA-CD151 and HCCLM3-shRNA-integrin β1 (E). The tumor volumes of CD151-HepG2-derived xenografts were significantly larger than those of HepG2-CD151-shRNA-CD151 and HepG2-CD151-shRNA-integrin β1 (E). Serial sections showed that the pulmonary metastasis rates and metastatic tumor clusters in the HCCLM3-mock group were higher than that of HCCLM3-shRNA-CD151 group and the HCCLM3-shRNA-integrin β1 group. The pulmonary metastasis rates of CD151-HepG2 were markedly higher that of HepG2-CD151-shRNA-CD151 and HepG2-CD151-vshRNA-Integrinβ1 groups (F).

Cell migration assays showed an apparent decrease in the mobility of HCCLM3 cells transfected with shRNA-CD151 or shRNA-integrin β1 (Fig. 3C). However, after transfection with the CD151 plasmid, HepG2 cells had increased migratory capabilities. Representative photography indicated accelerated closure in HCCLM3-mock and HepG2-CD151 cells, compared to shRNA-CD151-HCCLM3, shRNA-integrin β1-HCCLM3, HepG2-CD151-shRNA-CD151, and HepG2-CD151-shRNA-integrin β1 cells (Fig. 3C). The aforementioned data indicate that CD151 likely increases the invasion and mobility of HCC cells in an integrin β1-dependent manner.

ELISA assays showed that the concentration of matrix metalloproteinase 9 (MMP9) in the supernatant of HCCLM3-mock cells was significantly higher than that of shRNA-CD151-HCCLM3 and shRNA-integrin β1-HCCLM3 cells (Fig. 3D). Similarly, after transfection with the CD151 plasmid, HepG2-CD151 cells showed increased secretion of MMP9. However, when HepG2-CD151 cells were interfered with shRNA-CD151 or shRNA-integrin β1, they showed decreased secretion of MMP9 (Fig. 3D). Under these conditions, no significant changes in the MMP2 expression were observed in the modified HCC cells interfered with shRNA-CD151 or shRNA-integrin β1, compared to parental cells (Fig. 3D). These data indicate that CD151 forms a complex with integrin β1 and modulates MMP9 expression and secretion.

Interaction of proteins within the CD151/integrin β1 complex promotes HCC metastasis in vivo

To further investigate the interaction and role of the CD151/integrin β1 complex in metastasis, we inoculated HCC cells in liver parenchyma of nude mice. Tumor volumes of HCCLM3-mock-derived xenografts were 1.95±0.6 cm3, which were significantly larger than those of HCCLM3-shRNA-CD151 (0.71±0.10 cm3) and HCCLM3-shRNA-integrin β1 (0.59±0.06 cm3). Tumor volumes of CD151-HepG2-derived xenografts were 1.89±0.6 cm3, which were significantly larger than those of HepG2-CD151-shRNA-CD151 and HepG2-CD151-shRNA- integrin β1 (0.51±0.05 cm3 and 0.47±0.04 cm3, respectively, P<0.01; Fig. 3E). Serial sections confirmed that pulmonary metastasis rates, and metastatic tumor clusters per mouse were 100% (5/5) and 210±63 in the HCCLM3-mock group, but were 40% (2/5) and 124±55 in the HCCLM3-shRNA-CD151 group, 40% (2/5) and 164±46 in the HCCLM3-shRNA-integrin β1 group, 60% (3/5), and 145±43 in the CD151-HepG2 group. There was no lung metastasis in the HepG2-mock, HepG2-CD151-shRNA-CD151, and HepG2-CD151-vshRNA-Integrinβ1 groups (P<0.05; Fig. 3F).

Overexpression of the CD151-integrin β1 complex correlates with poor prognosis of HCC patients

Here, we aimed to investigate the role of the CD151/integrin β1 complex in a larger series of HCC patients. To this end, we used immunohistochemistry to determine the expression of the CD151/integrin β1 complex in consecutive tissue microarray (TMA) slides consisting of 301 HCC and adjacent notumorous samples (Fig. 4A–J). As reported in our previous study, CD151 was mostly located on the membrane of tumor cells [8]. Strong positive integrin β1 expression was observed in most HCC cells, as well as the stroma fibroblasts and epithelial cells of the bile duct. Integrin β1 expression in tumor cells was localized in the cytoplasm, and had a diffuse or granular pattern (Fig. 4A–J). We then analyzed the relationship between expression of the CD151/integrin β1 complex and clinicopathological features of HCC. HCC characterized by microvascular invasion, large tumor (>5 cm) size, and high TNM stage, were prone to higher expression of the CD151/integrin β1 complex (Table 2). Kaplan-Meier analysis revealed that patients with high levels of CD151 expression had a poorer prognosis in terms of shorter OS and higher recurrence rates, compared to those with low expression (Fig. 5A and B). Expectedly, integrin β1 expression alone did not correlate to prognosis in this cohort of patients (Fig. 5C and D). Interestingly, patients were classified into four sub-groups according to their CD151 and integrin β1 density. The sub-group with high expression of the CD151/integrin β1 complex had the poorest prognosis of the whole cohort of patients (Fig. 5E and F). Univariate analysis revealed that CD151, microvascular invasion, and TNM showed prognostic significance, with poor prognosis for both OS and recurrence (Table 3). However, integrin β1 expression alone was not related to OS or recurrence. Multivariate analysis showed that CD151 and CD151/integrin β1 complex expression were independent predictors for OS or recurrence (Table 3). The aforementioned data indicates that CD151 functions as a molecular facilitator in the progression of HCC in an integrin β1-dependent manner.

Figure 4. Expression of CD151/integrin β1 complex in HCC patients by immunohistochemistry.

Figure 4

Open in a new tab

After identification by H&E staining (A1, B1, C1, D1, E1, F1, G1, H1, I1, and J1), CD151 was mostly located on the membrane of tumor cells, with comparable variation (A2, B2, C2, D2, E2, F2, G2, H2, I2, and J2) and strong integrin β1 expression in most HCC cells, stroma fibroblasts, and epithelial cells of the bile duct (A3, B3, C3, D3, E3, F3, G3, H3, I3, and J3). A and B refer to adjacent nontumoral tissue. Representative tumor tissues are shown :C and D high expression of CD151 and integrin β1, E and F high expression of CD151 and low expression of integrin β1, G and H high expression of integrin β1 and low expression of CD151, I and J low expression of CD151 and integrin β1.

Table 2. Correlations of CD151 and integrin β1 expression with clinicopathological features of 301 HCCs.

variables CD151 staining P value Integrinβ1 staining P value
high low high low
Sex
male 116 137 0.597 128 125 0.734
female 24 24 23 25
Age, year
≥52 73 80 0.671 83 70 0.15
<52 67 81 68 80
HBsAg
positive 115 130 0.756 123 122 0.978
negative 25 31 28 28
Preoperative treatment
yes 63 62 0.254 67 58 0.315
no 77 99 84 92
Child -Pugh score*
A 140 160 1 150 150 1
B 0 1 1 0
Serum AFP, ng/ml
≤20 64 82 0.366 81 65 0.074
>20 76 79 70 85
Tumor number
single 115 145 0.046 129 131 0.63
multiple 25 16 22 19
Microvascular invasion
yes 16 6 0.01 16 6 0.028
none 125 155 135 144
Tumor encapsulation
complete 55 54 0.301 50 59 0.262
none 85 107 101 91
Tumor differentiation
I/II 39 50 0.544 42 47 0.504
III/IV 101 111 109 103
Tumor size (cm)
≤5 71 102 0.027 78 95 0.04
>5 69 59 73 55
TNM stage
I/II 39 21 0.001 37 23 0.046
III 101 140 114 127
Open in a new tab

Abbreviations and Note: HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; TNM, tumor node metastasis; HBsAg, hepatitis B surface antigen; NS, not significant; The X2 test was used for comparison between groups. 50% for CD151, Median of intensity for integrin β1 were used as the cut-off value.

*Fisher's exact test.

Figure 5. Prognostic roles by Kaplan-Meier analysis.

Figure 5

Open in a new tab

Kaplan-Meier analysis revealed that patients with high CD151 expression had poor prognosis in terms of overall survival (A) and recurrence rate (B). However, no difference in overall survival (C) and recurrence rate (D) was observed between high integrin β1 expression group and low expression group. Patients were classified into four groups according to their CD151 and integrin β1 density: group I, high expression of both markers; group II, high expression of CD151 alone; group III, high expression of integrin β1 alone and group IV, low expression of both markers. Kaplan-Meier analysis revealed that HCC patients with overexpression of CD151/ integrin β1 presented with the worst overall survival (E) and the highest cumulative recurrence rate (F).

Table 3. Univariate and multivariate analyses of factors associated with survival and recurrence.

factor Overall survival Cumulative Recurrence
Univariate Multivariate Univariate Multivariate
P HR 95% CI P P HR 95% CI P
Sex (male versus female) 0.835 NA 0.487 NA
Age (<52 versus >52 years) 0.234 NA 0.641 NA
HBsAg (negative versus positive) 0.563 NA 0.215 NA
Child-Pugh score (A versus B) 0.637 NA 0.626 NA
Serum AFP (>20 versus <20 ng/mL) 0.037 1.335 0.978–1.822 NS 0.379 NA
Tumor size (>5 versus <5 cm) 0.002 1.378 1.006–1.887 0.046 0.114 NA
Tumor number (multiple versus single) 0.003 1.637 1.098–2.440 0.015 0.083 NA
Microvascular invasion (yes versus no) <0.001 1.886 1.114–3.191 0.018 0.018 1.917 1.053–3.488 0.033
Tumor encapsulation (none versus complete) 0.002 1.323 0.952–1.841 NS 0.087 NA
Tumor differentiation (III/IV versus I/II) 0.018 1.365 0.989–1.884 NS 0.061 NA
TNM stage (I/II versus III) <0.001 NA 0.001 NA
CD151 density (<50% versus >50%) 0.002 0.698 0.512–0.951 0.023 <0.001 0.555 0.396–0.777 0.001
Integrin β1 density (high versus low) 0.153 NA 0.054 NA
CD151/ Integrin β1 density* 0.002 0.003 <0.001 <0.001
I verse II 1.571 1.091–2.262 0.015 2.028 1.366–3.013 <0.001
I verse III 0.847 0.515–1.392 NS 0.860 0.491–1.506 NS
I verse IV 0.718 0.438–1.174 NS 0.646 0.380–1.096 NS
Open in a new tab

The Cox proportional hazards regression model was used.

Abbreviations: AFP, alpha-fetoprotein; CI, confidence interval; HBsAg, hepatitis B surface antigen; HR, hazard ratio; NA, not adopted; NS, not significant.

*Patients were classified into four groups according to their CD151 and Integrin β1 density: group I (n = 93) had high expression of CD151 and Integrin β1, group II (n = 47) had high expression of CD151 but low Integrin β1 expression, group III (n = 58) had high expression of Integrin β1 but low CD151 expression and group I V (n = 103) had low expression of CD151 and Integrin β1. Individual variables were first adopted for their prognostic significance by multivariate analysis, and then the combination of CD151 and Integrin β1 was analyzed.

Discussion

We previously identified tetraspanin CD151 as a key molecule involved in the invasion and metastasis of HCC, most likely through formation of functionally relevant complexes [8], [18], [19]. Here, we used large-scale proteomics screening techniques [29], [30] to develop a map of the extensive protein-protein “interactome” network centered on tetraspanin CD151 in HCC cells.

An important result in this study was that CD151 organized “a tetraspanin web” with several partners, including integrins α6 and β1, c-Met, Moesin, thrombospondin-1 precursor, neuropilin 1, and GIPC PDZ domain containing family, member 1, and served as a molecular facilitator or adaptor for cell migration. Among these molecules, the integrins were considered the most important molecular partners for CD151 [9]. CD151 contains two extracellular loops and two short cytoplasmic tails. The large extracellular loop is necessary and sufficient for mediating the stable interaction of CD151 with the integrin subunit [11], [12]. Previous reports have revealed that CD151 can form a direct and highly stoichiometric lateral complex with integrins α3, α6, α7, β1, and β4, which are able to resist detergents such as digitonin and Triton X-100 [23]. Anti-CD151 antibodies or CD151 mutants can selectively inhibit integrin α3 and α6-dependent cell migration, whereas upregulation of CD151 enhances experimental metastasis of colon carcinoma and fibrosarcoma cells [31]. Mass spectrometry data analysis showed that integrins α3, α6 and β1 serve as molecular partners for CD151. However, integrin α3 could not be identified by Western blot analysis after immunoprecipitation, which is mainly attributed to the extremely low expression of integrin α3 in HCC cells [8], [13]. It has been well documented that the CD151/integrin complex acts as a functional unit for modulation of physiological and pathological processes, including cell migration, neurite outgrowth, and cell morphology [11], [13], [32]. The identified tetraspanin web provided direct evidence for our previous notion that CD151 formed a complex with integrin α6, and induced epithelial–mesenchymal transition in HCC cells [8]. Integrin β1 not only acts as an adhesive receptor for laminins, but also as an intracellular signaling platform that promotes cell migration and invasion [33]. Our results also showed that the integrin β1 subunit often forms structural complexes with the CD151 and integrin α subunit, in line with a previous report [9]. An important partner in the tetraspanin web is c-Met (hepatocyte growth factor receptor). Recent studies have demonstrated the interaction between tetraspanins and c-Met. Tetraspanin CD82 forms a complex with c-Met and inhibits hepatocyte growth factor (HGF)-induced cancer cell migration by inactivation of small GTP-binding proteins in the Rho family, via c-Met adapter proteins [34]. CD82 also complexes with the ganglioside GM2/GM3 heterodimer, and inhibits cell motility through the CD82-c-Met or integrin-c-Met pathways [15]. CD151 can enhance receptor signaling through integrin β4-mediated pathways and control c-Met-dependent neoplastic growth [35]. Our previous data also revealed that CD151 probably interacted with c-Met and had an adverse effect on the prognosis of HCC patients through HGF/c-Met pathways [18]. Importantly, the proteins Moesin, thrombospondin-1 precursor, neuropilin 1, and GIPC PDZ domain containing family, member 1, were observed in the tetraspanin web. Recently, accumulating evidence has demonstrated that these proteins interact with tetraspanins and modulate cell migration. Upregulation of tetraspanin CD81 expression at the NK cell can induce phosphorylation of ezrin/radixin/moesin proteins and lead to NK cell polarization, thereby facilitating NK cell migration towards various chemokines/cytokines [36]. The Ig superfamily proteins, EWIs, act as linkers to connect tetraspanin-associated microdomains to the actin cytoskeleton, to regulate cell motility and polarity via direct interaction with ezrin/radixin/moesin (ERM) proteins [37]. However, the interaction between CD151 and these proteins, and their roles in HCC cell migration remains to be determined. In addition to having purely structural functions as organizers and facilitators, CD151 also regulates various aspects of trafficking and biosynthetic processing of associated receptors as identified in the tetraspanin network, in line with a previous report [38]. Of the 57 proteins identified in Table 1, 47 have not previously been linked to CD151. Regarding these potential CD151 partners, further experiments are needed to confirm their direct association with CD151, to assess the extent of this association, and to determine functional implications.

Another implication about the characterized network centered on CD151, is that it explains the functional complexity of CD151, and provides a clue for uncovering the mystery. Traditionally, overexpression of CD151 facilitates integrins and growth factor receptors signals, activates Rac and Cdc42, and serves as a transmembrane linker between extracellular integrin domains and intracellular cytoskeleton/signaling molecules, leading to the regulation of actin cytoskeleton, cell spreading, tumor cell motility, and metastasis [26]. However, several papers have reported that expression of CD151 has a negative influence on cell migration and invasiveness [25], [26], [27]. The identified tetraspanin web addressed these conflicting results. On one hand, CD151 can form functional complexes with different partners and give rise to different roles in cell adhesion, migration, and metastasis in different cells. On the other hand, the molecular partners in the tetraspanin web play an opposite role in the function of CD151. For example, the low-density lipoprotein receptor precursor, one of the molecular partners identified in this study, was found to counteract the role of CD151 in the progression of HCC (unpublished data). Another important result that arose from our studies is that CD151 played a crucial role in cell migration, invasiveness, and metastasis of HCC in an integrin β1-dependent manner. Overexpression of CD151 has been associated with HCC progression [8], [18], [19]. Recent studies have demonstrated that the altered expression of β1 integrins in HCC, and overexpression of β1 integrins correlate with aggressive phenotypes and metastasis of HCC [7], [39]. However, it is undeniable that HepG2 with very low level of metastatic potential displays high level of β1 integrin, and that a highly positive proportion of β1-integrin expression is observed in most HCC samples [8]. Tetraspanins provide a platform to organize proteins on the cell membrane, which has great flexibility. Each tetraspanin may have specific partners for interaction and can interact with different proteins and in that way contribute to variability, and probably functional specificity, of the complex [40]. Furthermore, the exposure of a CD151 epitope involved in this binding is cell-type specific, and may vary depending on the physiological and pathological status of the tissues involved [21]. We noted that CD151 formed a functional complex with integrin β1 in TEM. We postulated that integrin β1, in concert with associated-CD151 molecules, might support HCC progression, rather than individual integrin β1 molecules. In this study, downregulation of CD151 in HCC cells had no effect on the expression of integrin β1, and vice versa. When either CD151 or integrin β1 was silenced, HCC cells with high expression of CD151/integrin β1 complex displayed markedly impaired motility, invasiveness, and metastasis both in vitro and in vivo. However, integrin β1-silenced HepG2 cells with low levels of CD151 expression had the same low mobile velocity and weak invasion as that of the parental cell lines. Interestingly, re-expressing CD151 in HepG2 cells reversed the mobile and invasive defects. Moreover, CD151 or integrin β1-slienced HCC cell with high expression of CD151/integrin β1 complex displayed the markedly decreased secretion of MMP9, which was considered as the most important molecule for matrix remodeling [41]. These data indicate that loss of CD151 disrupts integrin β1 association with tetraspanin-enriched microdomains, impairs integrin β1 internalization in cells migrating [31], and modulates the extracellular matrix remodeling through influence of MMP9 secretion [19], [20]. Even more importantly, we identified a role of the CD151/integrin β1 complex in the clinical setting of HCCs. HCC patients with high level of CD151/integrin β1 complex expression had the worst prognosis of all populations examined. A key property of integrins is that they can assume multiple functional states. Integrins on normal cells are mostly inactive and are activated by several stimuli [5]. Our previous study also showed that CD151 could amplify the function of integrin α6 [8]. Therefore, β1 integrins expressed on HCC cells probably harbored various levels of constitutive activity, and at the larger scale, its role in the progression of HCC was activated by the overexpression of CD151.

In conclusion, strong lateral CD151/integrin β1 complex is functionally important, and CD151 serves as a key player in integrin β1-dependent matrix remodeling, cell spreading, and metastasis. Disassociation with CD151-integrin β1 complex is a good choice for developing an anti-metastasis strategy for HCC.

Materials and Methods

Cell lines

Human HCC cell lines HCCLM3, MHCC97H, MHCC97L (established in Liver Cancer Institute of Zhongshan Hospital, Fudan University), PLC/PRF/5, Hep3B and HepG2 (American Type Culture Collection, Manassas, VA), and normal hepatocytes L-02 (Chinese Academy of Sciences, Shanghai) were used in this study. Cells were maintained in a 37°C humidified incubator in the presence of 5% CO2.

Immunoisolation of CD151-containing complexes and in-gel tryptic digestion

To identify CD151-associated molecules, immunoprecipitation was performed as previously described [20]. Briefly, 5×108 HCCLM3 cells were lysed in 40 ml lysis buffer containing 10 mM Tris, pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 1% Brij 97, and protease inhibitors for 2 h at 4°C. The lysate was centrifuged at 16,000×g for 15 min, and the supernatant was precleared with a combination of protein A/G-agarose beads (Amersham Biosciences, PA USA) precoated with BSA and goat serum (Sigma-Aldrich, MO, USA) for 2 h at 4°C. Then, the lysate was incubated with a specific antibody coupled to protein A/G-agarose beads for 2 h at 4°C. Immobilized immune complexes were then washed four times with lysis buffer, eluted using 1% Triton X-100, and acetone-precipitated. Proteins were resolved by 10% SDS-polyacrylamide gel electrophoresis (PAGE) under non-reducing conditions, and detected by immunoblot analysis using specific antibodies.

Gels were stained with colloidal Coomassie Blue (Bio-Rad, CA USA), excised, and destained. Then, gel pieces were incubated in 100% acetonitrile for 10 min, dried, and incubated in 100 mM ammonium bicarbonate containing 10 mM dithiothreitol (DTT) for 30 min at 56°C. After cooling to room temperature, gel pieces were incubated with 55 mM iodoacetamide in 100 mM ammonium bicarbonate for 20 min in the dark, at room temperature, washed with 100 mM ammonium bicarbonate for 20 min, dehydrated with 100% acetonitrile (ACN), and dried. Then, gel pieces were digested with 100 ng of trypsin and 25 mM ammonium bicarbonate (Roche Applied Science, IN USA) overnight at 37°C. Peptides were extracted successively with 50 µl of 5% formic acid for 15 min, and 100 µl of 100% acetonitrile for another 15 min at 37°C.

Two-dimensional liquid chromatography coupled with tandem mass spectrometry (2D-LC-MS/MS) and data analysis

Proteins were vacuum-dried and resuspended in 5% ACN containing 0.1% formic acid. LC-MS/MS analyses were performed using a Nano Aquity UPLC system (Waters, Milford, MA) coupled to a LTQ Orbitrap XL mass spectrometer (Thermo Electron, Bremen, Germany), and equipped with an online nanoelectrospray ion source (Michrom Bioresources, Auburn, CA). The capillary column used in this study was a BEH300 C18 reverse phase (75-µm inner diameter, 20 cm). To perform LC-MS/MS analysis, samples were injected into the trap-column at a flow rate of 15 µl/min for 3 min, and subsequently a 3-step linear 105-min gradient (flow rate, 300 nl/min) from 5 to 80% acetonitrile in 0.1% (v/v) formic acid was performed. All data were collected in centroid mode using a data-dependent acquisition mode. After acquisition of a full MS scan (m/z: 400–2000 Da), in the first scan event, the three most intense ions present above a threshold of 105 counts were subsequently isolated for fragmentation (MS/MS scan). The collision energy for the MS/MS scan events was preset at a value of 25%. All MS/MS data were identified using SEQUEST (v.28, Bioworks 3.3 software package, Thermo Electron) against the Human International Protein Index (IPI) database (IPI human v3.45 FASTA with 71983 entries). The search results were checked by examination of the Xcorr (cross-correlation) and the ΔCn (delta normalized correlation) scores. In this study, an Xcorr value of greater than 1.5, 2.0, and 2.5, respectively, for 1, 2, and 3 charged peptides and a ΔCn greater than 0.1 were accepted as positive identification [28]. These peptides were converted into a gene symbol and rearranged according to GO functional enrichment provided by DAVID website. Then, “tetraspanin web” centered on CD151 was organized by the cytoscape (Ver: 2.6.2, http://www.cytoscape.org/), a package to build network, searching target genes that interacted with CD151 and removing the genes that were not contained in our target genes using data source (NCBI Entrez EUtilities Web Service Client).

Transfection of lentiviral vectors CD151 or integrin β1 shRNA

The pGCSIL-GFP-shRNA-CD151 [8] and pGCSIL-GFP-shRNA-integrin β1 were constructed (pGCSIL, a lentiviral vector, Shanghai GeneChem Co. Ltd); pGCSIL-GFP was used as a negative control. The sequence of shRNA targeting integrin β1 is as follows: 5′-GACTGAGCATGATGAAAGT-3′. The lentiviral vectors and pHelper were co-transfected into 293T cells. Culture supernatants were collected, concentrated, and used as virus stocks. The lentivirus was transfected into HCCLM3 cells with a multiplicity of infection (MOI) of 20–50 (optimal MOI, 30). pcDNA3-CD151cDNA plasmids, kindly provided by Hansoo Lee (Kangwon National University, Korea), were transfected into HepG2 cells using a lentiviral vector as previously described [8].

Immunocytochemistry (ICC), confocal laser scanning microscopy and flow cytometry

HCCLM3 cells were used to show the co-localization of CD151 and integrin β1. Monoclonal mouse anti-human CD151 (11G5a, 1∶100; Serotec, OX5 1GE, UK) and monoclonal rabbit anti-human integrin β1 antibody (EP1041Y, 1∶250; abCAM, CA USA) were used for fluorescence cytostaining as previously described [8]. The localization of CD151 and integrin β1 was detected by confocal laser scanning microscopy (LSM510; Zeiss, Germany). Anti-human integrin β1/FITC antibody (BD Pharmingen, CA, USA) was used to investigate the expression of integrin β1 in HCCLM3, MHCC97H, MHCC97L, PLC/PRF/5, Hep3B, and HepG2 via flow cytometry using MoFlo (DakoCytomation, Fort Collins, CO) [18]. Isotype-matched immunoglobulin G served as a control. Propidium iodide (1 µg/ml, Sigma-Aldrich, MO, USA) was added to exclude dead cells.

Immunoblotting and reverse transcription polymerase chain reaction (RT-PCR)

Immunoblotting and RT-PCR were used to detect the expression of CD151 and integrin β1 in HCCLM3, short hairpin RNA (shRNA)-CD151-HCCLM3, HCCLM3-Mock, shRNA-integrin β1-HCCLM3, MHCC97H, MHCC97L, PLC/PRF/5, Hep3B cells, HepG2-CD151 (HepG2-pcDNA3-CD151-cDNA), HepG2-Mock (HepG2-pcDNA3), HepG2-CD151-shRNA-CD151 and HepG2-CD151-shRNA-integrin β1 [19], [42]. Mouse anti-human CD151 monoclonal antibody (11G5a, 1∶200; Serotec, OX5 1GE, UK) and monoclonal rabbit anti-human integrin β1 antibody (EP1041Y, 1∶500; abCAM, CA, USA) were used for immunoblotting, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 1∶5000; Chemicon, Billerica, MA, USA) was used as an internal control. Primers of CD151 for RT-PCR analysis: 5′-ACTTCATCCTGCTCCTCATCAT-3′ and 5′-TCCGTGTTCAGCTGCTGGTA-3′; integrin β1: 5′-GCTAAAATGCTGGCACCCTAA-3′ and 5′-ATAGTGCTCCCCAATGAAAGTAGAGA-3′; GAPDH: 5′-GGCATCCTGGGCTACACTGA-3′ and 5′-GTGGTCGTTGAGGGCAATG-3′. The relative expression of messenger RNA (mRNA) was analyzed by the comparative cycle threshold (Ct) method. GAPDH was used as an internal standard. All experiments were performed in triplicate.

Invasion assay, migration assay, and enzyme-linked immunosorbent assay (ELISA)

Invasive ability of shRNA-CD151-HCCLM3, HCCLM3-Mock, shRNA-integrin β1-HCCLM3, HepG2-CD151, HepG2-Mock, HepG2-CD151-shRNA-CD151 and HepG2-CD151-shRNA-integrin β1 cells were assayed as described elsewhere [19].

Migration ability of shRNA-CD151-HCCLM3, HCCLM3-Mock, shRNA-integrin β1-HCCLM3, HepG2-CD151, HepG2-Mock, HepG2-CD151-shRNA-CD151 and HepG2-CD151-shRNA-integrin β1 were detected as described elsewhere [43].

The concentrations of MMP9 and MMP2 in a conditioned medium from shRNA-CD151-HCCLM3, HCCLM3-Mock, shRNA-integrin β1-HCCLM3, HepG2-CD151, HepG2-Mock, HepG2-CD151-shRNA-CD151 and HepG2-CD151-shRNA-integrin β1 were determined by ELISA with a human MMP9 ELISA kit (R&D Systems) and a human MMP2 ELISA kit (R&D Systems) respectively, essentially as described previously [19]. All experiments were performed in triplicate.

Metastasis assay

Metastasis nude model of shRNA-CD151-HCCLM3, HCCLM3-Mock, shRNA-integrin β1-HCCLM3, HepG2-CD151, HepG2-Mock cells, HepG2-CD151-shRNA-CD151 and HepG2-CD151-shRNA-integrin β1 was constructed [44]. Serial sections were made for every tissue block from the lung, and the total number of lung metastases was counted under the microscope as described previously [18]. Each group included five animals.

Patients and follow-up

Tumor specimens taken from areas next to the margin of tumors were obtained from 301 consecutive patients who underwent curative liver resection between 1997 and 2000 in Zhongshan Hospital of Fudan University. Curative resection was defined as complete resection of all tumor nodules and the cut surface being free of cancer by histologic examination; having no cancerous thrombus in the portal vein (main trunk or two major branches), hepatic veins, or bile duct, and having no extrahepatic metastasis [19]. HCC diagnosis was based on the World Health Organization criteria. Tumor differentiation was defined according to the Edmondson grading system [45]. Liver function was assessed by Child-Pugh score system. Tumor staging was determined according to the sixth edition of tumor node metastasis classification of Union Internationale Contre le Cancer. Detailed clinicopathological characteristics were listed in Table 2. Ethical approval was obtained from the research ethics committee of Zhongshan Hospital, and written informed consent was obtained from each patient. Follow-ups were terminated until March, 2007. The median follow-up was 64 months (range, 4–121 months). Follow up procedures were described in our previous study [19]. Treatment modalities after relapse were given according to uniform guidelines as previously described [19].

Tissue microarray (TMA) and immunohistochemistry

TMA was constructed as described previously [19]. The mouse anti-human CD151 (1∶100, 11G5a, Serotec, OX5 1GE, UK) and monoclonal rabbit anti-human integrin β1 antibody (EP1041Y, 1∶250; abCAM) antibodies were used to detect the expression of CD151 and integrin β1, respectively, based on a two-step protocol as previously described [8]. The density of positive staining of CD151 and integrin β1 was measured as described elsewhere [8].

Statistical analysis

Statistical analysis was done with SPSS software, version 12.0 (SPSS, Chicago, IL). Overall survival (OS) and time to recurrence were defined as described previously [19]. The cumulative recurrence and OS rates were calculated by the Kaplan-Meier method and the log-rank test. Cox's proportional hazards regression model was used to analyze independent prognostic factors. P<0.05 was set as the level of statistical significance.

Supporting Information

Figure S1

Expression of integrin α1, α2, α3, α6 and β1 mRNA in HCCLM3 cells. Expression of integrin α1, α2, α3, α6 and β1 mRNA in HCCLM3 cells was detected by qRT-PCR.

(TIF)

Click here for additional data file. (309.8KB, tif)

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by the National Key Sci-Tech Special Project of China (2008ZX10002-022; 2008ZX10002-019), the Major Program of NSFC (N.81030038), the National Hi-Tech Research and Development Program of China (2007AA02Z479), National Natural Science Foundation (81071741; 30972949), the Ph.D. Programs Foundation of Ministry of Education of China (20090071120025), Shanghai Municipal Natural Science Foundation (11ZR1428300) and the special program of China Postdoctoral Science Foundation (201003236). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Ye QH, Qin LX, Forgues M, He P, Kim JW, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9:416–423. doi: 10.1038/nm843. [DOI] [PubMed] [Google Scholar]
  • 2.Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5:215–219. doi: 10.1016/s1535-6108(04)00058-3. [DOI] [PubMed] [Google Scholar]
  • 3.Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127:679–695. doi: 10.1016/j.cell.2006.11.001. [DOI] [PubMed] [Google Scholar]
  • 4.Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science. 1982;217:998–1003. doi: 10.1126/science.7112116. [DOI] [PubMed] [Google Scholar]
  • 5.Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11–25. doi: 10.1016/0092-8674(92)90115-s. [DOI] [PubMed] [Google Scholar]
  • 6.Huck L, Pontier SM, Zuo DM, Muller WJ. beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci U S A. 2010;107:15559–15564. doi: 10.1073/pnas.1003034107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Masumoto A, Arao S, Otsuki M. Role of beta1 integrins in adhesion and invasion of hepatocellular carcinoma cells. Hepatology. 1999;29:68–74. doi: 10.1002/hep.510290146. [DOI] [PubMed] [Google Scholar]
  • 8.Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, et al. CD151 amplifies signaling by integrin alpha6beta1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology. 2011;140:1629–1641. doi: 10.1053/j.gastro.2011.02.008. [DOI] [PubMed] [Google Scholar]
  • 9.Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005;6:801–811. doi: 10.1038/nrm1736. [DOI] [PubMed] [Google Scholar]
  • 10.Mazzocca A, Sciammetta SC, Carloni V, Cosmi L, Annunziato F, et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem. 2005;280:11329–11339. doi: 10.1074/jbc.M410161200. [DOI] [PubMed] [Google Scholar]
  • 11.Levy S, Shoham T. Protein-protein interactions in the tetraspanin web. Physiology (Bethesda) 2005;20:218–224. doi: 10.1152/physiol.00015.2005. [DOI] [PubMed] [Google Scholar]
  • 12.Levy S, Shoham T. The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol. 2005;5:136–148. doi: 10.1038/nri1548. [DOI] [PubMed] [Google Scholar]
  • 13.Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009;9:40–55. doi: 10.1038/nrc2543. [DOI] [PubMed] [Google Scholar]
  • 14.Rolink AG, Schaniel C, Busslinger M, Nutt SL, Melchers F. Fidelity and infidelity in commitment to B-lymphocyte lineage development. Immunol Rev. 2000;175:104–111. [PubMed] [Google Scholar]
  • 15.Todeschini AR, Dos Santos JN, Handa K, Hakomori SI. Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway. Proc Natl Acad Sci U S A. 2008;105:1925–1930. doi: 10.1073/pnas.0709619104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.He B, Liu L, Cook GA, Grgurevich S, Jennings LK, et al. Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating integrin alpha6-mediated cell adhesion. J Biol Chem. 2005;280:3346–3354. doi: 10.1074/jbc.M406680200. [DOI] [PubMed] [Google Scholar]
  • 17.Zijlstra A, Lewis J, Degryse B, Stuhlmann H, Quigley JP. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell. 2008;13:221–234. doi: 10.1016/j.ccr.2008.01.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology. 2009;49:491–503. doi: 10.1002/hep.22639. [DOI] [PubMed] [Google Scholar]
  • 19.Shi GM, Ke AW, Zhou J, Wang XY, Xu Y, et al. CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Hepatology. 2010;52:183–196. doi: 10.1002/hep.23661. [DOI] [PubMed] [Google Scholar]
  • 20.Hong IK, Jin YJ, Byun HJ, Jeoung DI, Kim YM, et al. Homophilic interactions of Tetraspanin CD151 up-regulate motility and matrix metalloproteinase-9 expression of human melanoma cells through adhesion-dependent c-Jun activation signaling pathways. J Biol Chem. 2006;281:24279–24292. doi: 10.1074/jbc.M601209200. [DOI] [PubMed] [Google Scholar]
  • 21.Sterk LM, Geuijen CA, van den Berg JG, Claessen N, Weening JJ, et al. Association of the tetraspanin CD151 with the laminin-binding integrins alpha3beta1, alpha6beta1, alpha6beta4 and alpha7beta1 in cells in culture and in vivo. J Cell Sci. 2002;115:1161–1173. doi: 10.1242/jcs.115.6.1161. [DOI] [PubMed] [Google Scholar]
  • 22.Testa JE, Brooks PC, Lin JM, Quigley JP. Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res. 1999;59:3812–3820. [PubMed] [Google Scholar]
  • 23.Yauch RL, Berditchevski F, Harler MB, Reichner J, Hemler ME. Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration. Mol Biol Cell. 1998;9:2751–2765. doi: 10.1091/mbc.9.10.2751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Shi GM, Xu Y, Fan J, Zhou J, Yang XR, et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol. 2008;134:1155–1163. doi: 10.1007/s00432-008-0407-1. [DOI] [PubMed] [Google Scholar]
  • 25.Chattopadhyay N, Wang Z, Ashman LK, Brady-Kalnay SM, Kreidberg JA. alpha3beta1 integrin-CD151, a component of the cadherin-catenin complex, regulates PTPmu expression and cell-cell adhesion. J Cell Biol. 2003;163:1351–1362. doi: 10.1083/jcb.200306067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Shigeta M, Sanzen N, Ozawa M, Gu J, Hasegawa H, et al. CD151 regulates epithelial cell-cell adhesion through PKC- and Cdc42-dependent actin cytoskeletal reorganization. J Cell Biol. 2003;163:165–176. doi: 10.1083/jcb.200301075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Sauer G, Kurzeder C, Grundmann R, Kreienberg R, Zeillinger R, et al. Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. Oncol Rep. 2003;10:405–410. [PubMed] [Google Scholar]
  • 28.Le Naour F, Andre M, Greco C, Billard M, Sordat B, et al. Profiling of the tetraspanin web of human colon cancer cells. Mol Cell Proteomics. 2006;5:845–857. doi: 10.1074/mcp.M500330-MCP200. [DOI] [PubMed] [Google Scholar]
  • 29.Li S, Armstrong CM, Bertin N, Ge H, Milstein S, et al. A map of the interactome network of the metazoan C. elegans. Science. 2004;303:540–543. doi: 10.1126/science.1091403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature. 2005;437:1173–1178. doi: 10.1038/nature04209. [DOI] [PubMed] [Google Scholar]
  • 31.Winterwood NE, Varzavand A, Meland MN, Ashman LK, Stipp CS. A critical role for tetraspanin CD151 in alpha3beta1 and alpha6beta4 integrin-dependent tumor cell functions on laminin-5. Mol Biol Cell. 2006;17:2707–2721. doi: 10.1091/mbc.E05-11-1042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Wright MD, Geary SM, Fitter S, Moseley GW, Lau LM, et al. Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol. 2004;24:5978–5988. doi: 10.1128/MCB.24.13.5978-5988.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Yang C, Zeisberg M, Lively JC, Nyberg P, Afdhal N, et al. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res. 2003;63:8312–8317. [PubMed] [Google Scholar]
  • 34.Takahashi M, Sugiura T, Abe M, Ishii K, Shirasuna K. Regulation of c-Met signaling by the tetraspanin KAI-1/CD82 affects cancer cell migration. Int J Cancer. 2007;121:1919–1929. doi: 10.1002/ijc.22887. [DOI] [PubMed] [Google Scholar]
  • 35.Franco M, Muratori C, Corso S, Tenaglia E, Bertotti A, et al. The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. J Biol Chem. 2010;285:38756–38764. doi: 10.1074/jbc.M110.145417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Kramer B, Schulte D, Korner C, Zwank C, Hartmann A, et al. Regulation of NK cell trafficking by CD81. Eur J Immunol. 2009;39:3447–3458. doi: 10.1002/eji.200939234. [DOI] [PubMed] [Google Scholar]
  • 37.Sala-Valdes M, Ursa A, Charrin S, Rubinstein E, Hemler ME, et al. EWI-2 and EWI-F link the tetraspanin web to the actin cytoskeleton through their direct association with ezrin-radixin-moesin proteins. J Biol Chem. 2006;281:19665–19675. doi: 10.1074/jbc.M602116200. [DOI] [PubMed] [Google Scholar]
  • 38.Berditchevski F, Odintsova E. Tetraspanins as regulators of protein trafficking. Traffic. 2007;8:89–96. doi: 10.1111/j.1600-0854.2006.00515.x. [DOI] [PubMed] [Google Scholar]
  • 39.Katabami K, Mizuno H, Sano R, Saito Y, Ogura M, et al. Transforming growth factor-beta1 upregulates transcription of alpha3 integrin gene in hepatocellular carcinoma cells via Ets-transcription factor-binding motif in the promoter region. Clin Exp Metastasis. 2005;22:539–548. doi: 10.1007/s10585-005-5260-x. [DOI] [PubMed] [Google Scholar]
  • 40.Yunta M, Lazo PA. Tetraspanin proteins as organisers of membrane microdomains and signalling complexes. Cell Signal. 2003;15:559–564. doi: 10.1016/s0898-6568(02)00147-x. [DOI] [PubMed] [Google Scholar]
  • 41.Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–174. doi: 10.1038/nrc745. [DOI] [PubMed] [Google Scholar]
  • 42.Shi GM, Xu Y, Fan J, Zhou J, Yang XR, et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol. 2008 doi: 10.1007/s00432-008-0407-1. [DOI] [PubMed] [Google Scholar]
  • 43.Yang XH, Richardson AL, Torres-Arzayus MI, Zhou P, Sharma C, et al. CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. Cancer Res. 2008;68:3204–3213. doi: 10.1158/0008-5472.CAN-07-2949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Li Y, Tang Y, Ye L, Liu B, Liu K, et al. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol. 2003;129:43–51. doi: 10.1007/s00432-002-0396-4. [DOI] [PubMed] [Google Scholar]
  • 45.Wittekind C. Pitfalls in the classification of liver tumors. Pathologe. 2006;27:289–293. doi: 10.1007/s00292-006-0834-1. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Figure S1

Expression of integrin α1, α2, α3, α6 and β1 mRNA in HCCLM3 cells. Expression of integrin α1, α2, α3, α6 and β1 mRNA in HCCLM3 cells was detected by qRT-PCR.

(TIF)

Click here for additional data file. (309.8KB, tif)

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES